Clinical trials
Glucose Intolerance trials in Canada with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Withdrawn | 3 |
| Terminated | 2 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| McGill University Health Centre/Research Institute of the McGill University Health Centre | 2 |
| University of Alberta | 2 |
| University of Calgary | 2 |
| University of Manitoba | 2 |
| Université de Sherbrooke | 2 |
| Western University, Canada | 2 |
| Guelph Food Research Centre | 1 |
| LMC Diabetes & Endocrinology Ltd. | 1 |
| Laval University | 1 |
| Marie-France Langlois | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glucose Intolerance | 23 |
| Insulin Resistance | 6 |
| Obesity | 4 |
| Prediabetic State | 4 |
| Diabetes Mellitus, Type 2 | 3 |
| Cognitive Dysfunction | 2 |
| Diabetes Mellitus | 2 |
| Metabolic Syndrome | 2 |
| Overweight | 2 |
| Communicable Diseases | 1 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.